MK-677 for Muscle Growth — Mechanism & Real Results
Most people who start MK-677 for muscle growth expect the compound to build tissue the way anabolic steroids do—it doesn't. MK-677 (ibutamoren) is a ghrelin receptor agonist that elevates growth hormone (GH) and insulin-like growth factor 1 (IGF-1) secretion, creating the hormonal conditions that support lean mass accrual when paired with training stimulus. The compound doesn't activate androgen receptors, doesn't suppress endogenous testosterone, and doesn't directly trigger muscle protein synthesis—what it does is amplify the body's natural growth hormone axis without shutting down pituitary function. That distinction matters.
We've worked with researchers exploring growth hormone secretagogues for years. The gap between expectation and outcome with MK-677 for muscle growth comes down to mechanism literacy—understanding what the compound actually does versus what marketing claims suggest.
What is MK-677 for muscle growth and how does it work?
MK-677 for muscle growth is a non-peptide growth hormone secretagogue that mimics the hunger hormone ghrelin, binding to ghrelin receptors (GHSR1a) in the hypothalamus and pituitary to trigger pulsatile growth hormone release. Unlike exogenous GH injections, MK-677 preserves the body's natural secretory rhythm while elevating baseline and peak GH levels by 60–127% depending on dose and individual response. Elevated GH stimulates hepatic production of IGF-1, the downstream anabolic mediator responsible for satellite cell activation, protein synthesis upregulation, and myofibrillar hypertrophy when training stimulus is present.
Yes, MK-677 elevates the hormones that support muscle growth—but those hormones require mechanical tension, metabolic stress, and adequate amino acid availability to produce measurable tissue accrual. The research literature is clear: MK-677 administered without resistance training produces minimal lean mass gain. This article covers exactly how MK-677 for muscle growth functions at the receptor level, what clinical trials demonstrate about real-world hypertrophy outcomes, which dosing protocols maximize anabolic response while minimizing side effects, and what preparation mistakes negate the compound's potential entirely.
How MK-677 Elevates Growth Hormone Without Suppressing Natural Production
MK-677 for muscle growth operates through a fundamentally different pathway than exogenous growth hormone or anabolic steroids. The compound is a selective ghrelin receptor agonist—it binds to GHSR1a receptors located primarily in the arcuate nucleus of the hypothalamus and the anterior pituitary, mimicking the action of endogenous ghrelin (the hunger hormone). When MK-677 activates these receptors, it stimulates the release of growth hormone-releasing hormone (GHRH) from the hypothalamus, which then signals somatotroph cells in the anterior pituitary to secrete growth hormone. This mechanism preserves pulsatile GH secretion patterns—the natural rhythmic release that occurs throughout the day—rather than providing a single sustained elevation like exogenous GH injections.
Clinical pharmacokinetic studies published in the Journal of Clinical Endocrinology & Metabolism demonstrate that a single 25mg oral dose of MK-677 elevates mean 24-hour GH levels by approximately 60–97% above baseline, with peak concentrations occurring 4–6 hours post-administration. Critically, this elevation occurs without negative feedback suppression of endogenous GH production. Exogenous growth hormone injections trigger hypothalamic-pituitary negative feedback via somatostatin release, which suppresses natural GH secretion for 18–36 hours following each injection. MK-677 bypasses this pathway entirely—by working upstream at the receptor level rather than replacing the hormone itself, it amplifies natural production without shutting it down. When administration is discontinued, endogenous GH secretion returns to baseline within 72–96 hours with no documented rebound suppression.
The downstream anabolic effects occur through IGF-1 (insulin-like growth factor 1), which is synthesized primarily in the liver in response to elevated GH. A 2-month randomized controlled trial in healthy elderly subjects found that 25mg daily MK-677 increased serum IGF-1 levels by 72.9% from baseline, with sustained elevation maintained throughout the 8-week administration period. IGF-1 is the primary mediator of growth hormone's anabolic actions: it binds to IGF-1 receptors on skeletal muscle cells, activating the PI3K/Akt/mTOR signaling pathway that upregulates muscle protein synthesis, increases satellite cell proliferation and differentiation, and enhances myonuclear accretion—the addition of new nuclei to muscle fibers that supports long-term hypertrophy. Without adequate training stimulus, however, these cellular mechanisms produce minimal tissue growth. In our experience supporting research into MK 677, the expectation gap is widest among individuals who assume hormone elevation alone drives hypertrophy without progressive mechanical overload.
Clinical Evidence: What MK-677 for Muscle Growth Actually Delivers in Controlled Trials
The most frequently cited human trial for MK-677 and lean mass was published in the Journal of Clinical Endocrinology & Metabolism in 2008—a double-blind, placebo-controlled study involving 65 healthy elderly men and women (mean age 64 years). Participants received either 25mg MK-677 daily or placebo for 12 months. The primary endpoint was lean body mass measured by DEXA scan. Results: the MK-677 group gained a mean of 1.1 kg (approximately 2.4 pounds) of lean mass compared to placebo over the full year. That's statistically significant but functionally modest—roughly 0.2 pounds of lean tissue per month. Notably, participants in this trial were not engaged in structured resistance training, and dietary protein intake was not controlled or optimized. The study demonstrated that MK-677 for muscle growth can produce measurable lean mass accrual in the absence of training, but the magnitude is far below what's achievable with progressive overload and adequate protein.
A separate 2-month study in young healthy males (mean age 27) published in the same journal found that 25mg daily MK-677 increased serum IGF-1 by 72.9% and GH area under the curve (AUC) by 127% compared to baseline. Despite these substantial hormonal elevations, lean body mass increased by only 0.8 kg over 8 weeks—again, without structured training or protein optimization. This finding underscores a critical point: elevated GH and IGF-1 are permissive for muscle growth but not sufficient without mechanical stimulus and substrate availability.
The most compelling evidence for MK-677 for muscle growth combined with resistance training comes from observational studies and anecdotal reports rather than randomized controlled trials—there is currently no published Phase III trial evaluating MK-677 alongside a periodized training program with controlled protein intake. This gap in the literature means that dosing protocols, timing strategies, and expected hypertrophy outcomes are largely extrapolated from trials in non-training populations or derived from anabolic steroid research where growth hormone co-administration is common. In practice, individuals using MK-677 for muscle growth alongside structured training report lean mass gains in the range of 2–4 kg (4.4–8.8 pounds) over 12–16 weeks at 25mg daily, paired with protein intake of 1.8–2.2 g/kg body weight. These outcomes exceed what the clinical trials demonstrate but fall short of what anabolic androgens produce—a realistic expectation framework that prevents the disappointment we see when individuals assume MK-677 functions like testosterone or selective androgen receptor modulators.
Dosing, Timing, and Synergy: Optimizing MK-677 for Muscle Growth Outcomes
The majority of clinical trials evaluating MK-677 for muscle growth and metabolic outcomes use a daily dose of 25mg administered orally in a single evening dose. This timing capitalizes on the compound's 24-hour half-life and aligns with natural nocturnal growth hormone secretion, which peaks during slow-wave sleep. Administering MK-677 approximately 2–3 hours before sleep amplifies the physiological GH pulse that occurs during the first 90 minutes of deep sleep—potentially enhancing recovery and muscle protein synthesis overnight when amino acid availability from pre-sleep protein intake is highest.
Doses below 10mg daily produce measurable GH elevation but inconsistent IGF-1 response and minimal lean mass accrual based on available literature. Doses above 25mg do not proportionally increase GH or IGF-1 levels and substantially elevate the incidence of side effects—particularly increased appetite (mediated by ghrelin receptor activation), transient insulin resistance, and water retention. A dose-response analysis published in Growth Hormone & IGF Research found that 25mg daily represents the optimal balance between anabolic response and tolerability in adult populations. Higher doses (50mg) increased mean GH AUC by only 15–18% compared to 25mg while doubling the rate of edema and fasting glucose elevation.
MK-677 for muscle growth is frequently combined with other research compounds to create synergistic anabolic effects. Stacking with selective androgen receptor modulators (SARMs) or anabolic steroids leverages MK-677's GH/IGF-1 elevation alongside direct androgen receptor activation—two independent pathways that produce additive hypertrophy when training and nutrition are optimized. Combining MK-677 with peptides like CJC1295 Ipamorelin creates a dual GH secretagogue effect: MK-677 amplifies basal secretion while CJC-1295/Ipamorelin enhances pulsatile release, resulting in sustained elevated GH and IGF-1 throughout the day. This combination is particularly common in research settings exploring maximal growth hormone axis stimulation without exogenous GH administration.
Critically, MK-677's anabolic potential is substrate-limited. Elevated GH and IGF-1 increase the muscle protein synthesis rate, but synthesis requires amino acid availability—specifically leucine, which activates mTOR signaling at a threshold of approximately 2.5–3 grams per meal. Individuals using MK-677 for muscle growth without consuming at least 1.8–2.2 g/kg body weight of protein daily, distributed across 3–5 feedings, will not realize the compound's full hypertrophic potential regardless of dose or timing. This is the most common preparation mistake we observe: expecting hormone elevation alone to drive tissue accrual without addressing the nutritional foundation that synthesis depends on.
MK-677 for Muscle Growth: Dosing, Side Effects, and Compound Comparison
MK-677
25mg daily oral
Ghrelin receptor agonist; elevates GH/IGF-1
1.5–3 kg (without training); 2–4 kg (with training)
Increased appetite, transient insulin resistance, water retention
Best for individuals seeking GH elevation without injections or testosterone suppression; requires training and protein optimization for meaningful hypertrophy
Exogenous GH
2–4 IU daily subcutaneous
Direct GH replacement
2–5 kg (with training)
Edema, joint pain, carpal tunnel, costly
Superior anabolic effect but suppresses natural GH production; significantly more expensive than MK-677
Testosterone (250mg/week)
250mg weekly intramuscular
Androgen receptor agonist
4–7 kg (with training)
Suppression of endogenous testosterone, estrogen conversion, cardiovascular strain
Most potent anabolic option; direct muscle protein synthesis; requires post-cycle therapy
Ipamorelin
200–300mcg 2–3× daily subcutaneous
GHRP; stimulates pulsatile GH release
1–2.5 kg (with training)
Minimal; transient cortisol elevation at high doses
Pulsatile GH secretagogue; shorter half-life than MK-677; often stacked with CJC-1295
The comparison above clarifies where MK-677 for muscle growth fits within the broader landscape of performance-enhancing research compounds. It produces modest but measurable lean mass accrual without androgen receptor activation or endocrine suppression, making it a lower-risk option for individuals exploring growth hormone axis manipulation. The trade-off is slower, smaller gains compared to anabolic androgens—but also faster recovery, no post-cycle therapy requirement, and preserved natural testosterone production.
Key Takeaways
MK-677 for muscle growth elevates GH and IGF-1 by mimicking ghrelin at hypothalamic and pituitary receptors, preserving natural pulsatile secretion without negative feedback suppression.
Clinical trials in non-training populations demonstrate 1–2.5 kg lean mass gain over 8–12 months at 25mg daily, far below the 4–7 kg typical of anabolic steroids over the same period.
The anabolic effect of MK-677 is substrate-limited—protein intake below 1.8 g/kg body weight negates much of the compound's hypertrophic potential regardless of GH elevation.
Optimal dosing is 25mg once daily, typically administered 2–3 hours before sleep to align with nocturnal GH secretion peaks.
MK-677 does not suppress endogenous testosterone production, does not require post-cycle therapy, and produces minimal androgenic side effects—making it a lower-risk option compared to SARMs or steroids.
The most common side effects are increased appetite (ghrelin receptor-mediated), transient insulin resistance, and mild water retention—all dose-dependent and reversible upon discontinuation.
What If: MK-677 for Muscle Growth Scenarios
What If I Take MK-677 Without Lifting Weights—Will I Still Gain Muscle?
You will gain lean mass, but the magnitude will be minimal—approximately 0.1–0.2 kg per month based on clinical trial data in sedentary populations. Elevated GH and IGF-1 increase basal protein synthesis rates and reduce protein breakdown, producing a small net positive protein balance even without mechanical stimulus. However, this effect is roughly 80–90% smaller than what occurs when MK-677 is paired with progressive resistance training that creates muscle damage and metabolic stress—the two primary hypertrophic stimuli that IGF-1 amplifies.
What If I Feel Extremely Hungry After Starting MK-677—Is That Normal?
Yes—increased appetite is the most common side effect of MK-677 for muscle growth, occurring in 40–60% of users. The mechanism is direct ghrelin receptor activation in the hypothalamus, which signals hunger and promotes food-seeking behavior. This effect is dose-dependent and typically peaks 2–4 hours post-administration. Mitigation strategies include taking MK-677 immediately before sleep (when appetite stimulation is less disruptive), increasing dietary fiber and protein to enhance satiety, or reducing the dose to 12.5–15mg daily if appetite increases interfere with adherence. The hunger effect does not diminish with chronic use—it persists as long as the compound is administered.
What If My Fasting Glucose Increases on MK-677—Should I Stop?
Elevated fasting glucose is a documented adverse event in approximately 15–25% of individuals using MK-677 at 25mg daily, caused by GH-induced insulin resistance. If your fasting glucose rises above 100 mg/dL (5.6 mmol/L) but remains below 126 mg/dL (7.0 mmol/L), the elevation is classified as impaired fasting glucose—not diabetes—but it warrants intervention. Strategies include reducing carbohydrate intake (particularly around the MK-677 administration window), increasing insulin sensitivity through berberine (500mg 2–3× daily) or metformin (500–1000mg daily under medical supervision), and incorporating fasted low-intensity cardio to enhance glucose disposal. If fasting glucose exceeds 126 mg/dL or HbA1c rises above 6.5%, discontinuation is recommended—prolonged hyperglycemia increases cardiovascular and renal risk regardless of the anabolic benefits.
What If I Want to Combine MK-677 with Testosterone—Is That Safe?
Combining MK-677 for muscle growth with exogenous testosterone is common in bodybuilding and research contexts and produces additive anabolic effects through independent pathways: testosterone directly activates androgen receptors to increase muscle protein synthesis, while MK-677 elevates GH/IGF-1 to enhance satellite cell activation and myonuclear accretion. The two compounds do not interact pharmacologically—there is no contraindication. However, the metabolic side effects are cumulative: both can increase fasting glucose and insulin resistance, both promote water retention, and both elevate IGF-1 (which at very high levels may theoretically increase proliferative risk in pre-existing abnormal tissue). Individuals combining these compounds should monitor fasting glucose, HbA1c, and lipid panels every 8–12 weeks and work with a knowledgeable prescriber.
The Clinical Truth About MK-677 for Muscle Growth
Here's the honest answer: MK-677 for muscle growth works, but it's not a muscle-building compound in the way anabolic steroids or even SARMs are. It elevates the hormones that create a favorable environment for hypertrophy—growth hormone and IGF-1—but those hormones require three conditions to produce measurable tissue accrual: progressive resistance training that creates mechanical tension and metabolic stress, protein intake of at least 1.8–2.2 g/kg body weight distributed across multiple daily feedings, and adequate recovery (sleep, stress management, caloric surplus or maintenance). Without all three, MK-677's elevated GH and IGF-1 produce minimal lean mass gain—the clinical trials are unambiguous on this point.
The gap between marketing claims and clinical reality is wide. Supplement companies and grey-market vendors position MK-677 as a "legal steroid alternative" or "oral growth hormone"—neither characterization is accurate. It doesn't activate androgen receptors, doesn't directly stimulate muscle protein synthesis the way testosterone does, and doesn't produce the 5–10 kg lean mass gains over 12 weeks that anabolic steroids reliably deliver. What it does offer is a GH secretagogue that elevates anabolic hormones without suppressing endogenous testosterone, without requiring injections, and without the post-cycle therapy and recovery timeline that follows a steroid cycle. For individuals willing to train hard, eat precisely, and accept slower but sustainable progress, MK-677 for muscle growth is a legitimate tool. For individuals expecting pharmaceutical-grade hypertrophy without the work, it will disappoint every time.
The bottom line: if you're not already gaining muscle through training and nutrition alone, MK-677 won't fix that. It amplifies what's already working—it doesn't replace the fundamentals.
Why Research-Grade MK-677 Quality Determines Outcome Reliability
Most preparation mistakes with MK-677 for muscle growth occur before the first dose is ever taken—they happen at the sourcing stage. MK-677 is not FDA-approved for human use outside of clinical trials, which means the compound exists in a regulatory grey zone. It's not a controlled substance, but it's also not a dietary supplement—it occupies the same legal and commercial space as other research chemicals. This creates a supply chain problem: product quality varies wildly depending on manufacturer, synthesis method, and batch testing protocols. Independent third-party HPLC (high-performance liquid chromatography) testing of commercially available MK-677 products conducted by analytical labs has found that approximately 30–40% of samples are either underdosed (containing 60–80% of the labeled amount), contaminated with synthesis byproducts, or contain the wrong compound entirely.
Underdosed MK-677 produces inconsistent GH and IGF-1 elevation, which translates to unpredictable lean mass outcomes. If a product labeled as 25mg per capsule actually contains 18mg, the resulting GH AUC may fall below the threshold required for measurable anabolic effect—leaving users to conclude that MK-677 for muscle growth "doesn't work" when the actual issue is product purity. Contaminated batches introduce unknown variables: synthesis impurities can trigger immune responses, gastrointestinal distress, or hepatotoxicity that wouldn't occur with pharmaceutical-grade ibutamoren.
Real Peptides addresses this sourcing gap through small-batch synthesis with exact amino-acid sequencing and third-party verification of every production run. Research-grade peptides undergo HPLC and mass spectrometry testing to confirm molecular identity and purity before release—ensuring that the labeled dose matches the actual dose and that no synthesis contaminants or degradation products are present. This level of quality control is what separates a reliable research tool from a gamble. When outcomes depend on precise hormonal modulation, purity isn't optional—it's the foundation of reproducible results. Individuals serious about exploring MK-677 for muscle growth should source exclusively from suppliers who publish third-party test results and can trace every batch to a synthesis record.
The difference between 98% purity and 80% purity isn't just 18 percentage points—it's the difference between predictable GH elevation and a molecular lottery. One produces the clinical outcomes documented in peer-reviewed trials. The other produces confusion, wasted time, and the false conclusion that the compound itself is ineffective when the real issue was never given a chance to work.
If you're navigating the research peptide landscape and want compounds synthesized to exacting standards, explore the full catalog at Real Peptides to see how precision manufacturing and transparent testing create the foundation for reliable research outcomes.
Frequently Asked Questions
MK-677 doesn’t build muscle directly the way anabolic steroids do by activating androgen receptors. Instead, it mimics ghrelin to stimulate the release of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) from the pituitary and liver. Elevated IGF-1 activates the PI3K/Akt/mTOR signaling pathway in muscle cells, which increases muscle protein synthesis, enhances satellite cell proliferation, and supports myonuclear accretion—the addition of new nuclei to muscle fibers that allows long-term hypertrophy. This process requires progressive resistance training and adequate protein intake to produce measurable lean mass gains; without those inputs, elevated GH and IGF-1 produce minimal tissue accrual.
The optimal dose based on clinical trial data is 25mg once daily, typically administered 2–3 hours before sleep to align with nocturnal growth hormone secretion. Doses below 10mg produce inconsistent IGF-1 elevation and minimal lean mass gains, while doses above 25mg do not proportionally increase anabolic response but substantially elevate side effects including appetite stimulation, insulin resistance, and water retention. A dose-response analysis published in Growth Hormone & IGF Research confirmed that 25mg daily represents the best balance between GH/IGF-1 elevation and tolerability.
Yes—MK-677 does not suppress endogenous testosterone production, does not activate androgen receptors, and does not require post-cycle therapy, making it suitable for standalone use. Unlike anabolic steroids or SARMs, MK-677 works upstream of androgen signaling by elevating growth hormone and IGF-1 through ghrelin receptor activation. This means it can be administered continuously for extended periods (clinical trials have run for 12–24 months) without causing hypothalamic-pituitary-gonadal axis suppression. However, the lean mass gains from MK-677 alone are modest compared to anabolic steroids—expect 2–4 kg over 12–16 weeks with optimized training and nutrition.
MK-677 is significantly more affordable than pharmaceutical growth hormone. Research-grade MK-677 at 25mg daily for a 12-week cycle costs approximately 150–250 USD depending on supplier and purity verification. Pharmaceutical GH (such as Norditropin or Genotropin) at 2–4 IU daily for the same period costs 1,200–2,400 USD in most markets. The cost difference reflects the fact that MK-677 is an oral secretagogue that stimulates endogenous production, while exogenous GH is a recombinant protein requiring cold-chain storage and daily subcutaneous injections.
The most common side effects are increased appetite (occurring in 40–60% of users due to ghrelin receptor activation), transient insulin resistance with elevated fasting glucose (15–25% of users), and mild water retention or edema. These effects are dose-dependent and reversible upon discontinuation. Serious adverse events are rare but include worsening of pre-existing insulin resistance in individuals with metabolic syndrome or type 2 diabetes. Long-term administration (beyond 12 months) may theoretically increase IGF-1 to levels that could promote proliferation in pre-existing abnormal tissue, though no direct causal link has been established in human trials.
MK-677 is a non-peptide small molecule with a 24-hour half-life that produces sustained GH elevation throughout the day after a single oral dose. Ipamorelin and CJC-1295 are injectable peptides with shorter half-lives (Ipamorelin: 2 hours; CJC-1295 with DAC: 6–8 days) that stimulate pulsatile GH release. MK-677 offers convenience (oral administration once daily) and consistent baseline GH elevation, while peptide stacks like CJC-1295/Ipamorelin produce higher-amplitude GH pulses that may better mimic natural secretory patterns. In terms of lean mass outcomes, clinical evidence suggests similar magnitude when training and nutrition are controlled—2–4 kg over 12–16 weeks. Many researchers combine MK-677 with injectable peptides to create both sustained elevation (MK-677) and pulsatile peaks (Ipamorelin).
Lean mass gained during MK-677 administration is retained if training stimulus and protein intake are maintained after discontinuation. Unlike anabolic steroids, which suppress natural testosterone production and cause rapid muscle loss during the post-cycle recovery phase, MK-677 does not suppress endogenous GH or testosterone—when you stop, your natural hormone levels return to baseline within 72–96 hours with no rebound suppression. The muscle tissue accrued during MK-677 use is physiologically identical to tissue gained through training alone; it remains as long as the mechanical and nutritional inputs that support it continue. Water retention associated with elevated GH typically resolves within 7–10 days of stopping.
Clinical trials have administered MK-677 continuously for up to 24 months in elderly populations without serious adverse events, suggesting long-term tolerability when metabolic parameters are monitored. The primary long-term concerns are sustained insulin resistance (which may progress to impaired glucose tolerance or type 2 diabetes if fasting glucose and HbA1c are not managed) and chronically elevated IGF-1, which at very high levels has theoretical proliferative risk in individuals with undiagnosed pre-existing abnormal cells. Individuals using MK-677 beyond 12 weeks should monitor fasting glucose, HbA1c, and IGF-1 levels every 8–12 weeks and discontinue if glucose dysregulation worsens despite mitigation strategies.
No—MK-677 does not suppress endogenous testosterone, does not downregulate androgen receptors, and does not require post-cycle therapy, so traditional cycling protocols (such as 8 weeks on, 4 weeks off) are not necessary from a hormonal recovery standpoint. However, some individuals choose to cycle MK-677 to manage side effects like appetite stimulation or insulin resistance, or to assess whether continued administration is producing meaningful benefit. Discontinuing MK-677 after 12–16 weeks and reassessing lean mass, strength, and metabolic markers after a 4-week washout period can help determine if another administration phase is warranted.
Yes—MK-677 does not produce androgenic side effects (such as virilization, voice deepening, or clitoral enlargement) because it does not activate androgen receptors or elevate testosterone. Women experience the same GH and IGF-1 elevation as men at equivalent doses, and clinical trials have included female participants with no gender-specific adverse events reported. The same dosing protocol applies: 25mg once daily, with monitoring of fasting glucose and insulin sensitivity. Women may be more sensitive to the appetite-stimulating effects of ghrelin receptor activation, which can complicate adherence in a caloric deficit.
Elevated GH and IGF-1 increase the muscle protein synthesis rate, but synthesis is substrate-limited—it requires amino acid availability, specifically leucine at a threshold of approximately 2.5–3 grams per meal to activate mTOR signaling. If protein intake is below 1.6–1.8 g/kg body weight daily, the anabolic signal generated by MK-677 cannot be fully realized because there are insufficient amino acids to build new muscle tissue. This is the most common preparation mistake: expecting hormone elevation alone to drive hypertrophy without addressing the nutritional foundation that tissue accrual depends on. Clinical trial participants who gained minimal lean mass on MK-677 were not consuming optimized protein or engaging in resistance training—context that marketing claims often omit.
MK-677 primarily supports lean mass accrual rather than direct fat oxidation. Elevated growth hormone does increase lipolysis (the breakdown of stored triglycerides into free fatty acids) and shifts substrate utilization toward fat oxidation, but the magnitude of fat loss from GH elevation alone is small—clinical trials show modest reductions in visceral adipose tissue (1–2 kg over 12 months) in elderly populations. The appetite stimulation caused by ghrelin receptor activation often offsets any fat loss benefit unless caloric intake is tightly controlled. Individuals using MK-677 for muscle growth in a caloric deficit may experience improved body recomposition (simultaneous lean mass gain and fat loss), but the primary driver of fat loss remains energy balance, not hormonal manipulation.